IO Biotech Announces 2023 First-Quarter Results
May 11, 2023 16:05 ET
|
IO Biotech
The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023.The Phase 3 trial protocol...
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
March 14, 2023 16:11 ET
|
IO Biotech
Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully...
IO Biotech to Participate in March 2023 Investor Conferences
February 22, 2023 07:00 ET
|
IO Biotech
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine...
IO Biotech Announces Appointment of Devin Smith as General Counsel
January 23, 2023 08:00 ET
|
IO Biotech
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine...
IO Biotech Provides Business Update
January 09, 2023 07:05 ET
|
IO Biotech
Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any...
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 09, 2022 16:07 ET
|
IO Biotech
- Preclinical data showing the rationale for two new pipeline candidates targeting the immunosuppressive effects of Arginase-1 (ARG1) and Transforming Growth Factor Beta 1 (TGFb1) were presented in...
IO Biotech Announces Third Quarter Results for 2022
November 09, 2022 16:05 ET
|
IO Biotech
Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company’s global Phase 3 combination trial of IO102-IO103 and KEYTRUDA®...
IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
November 03, 2022 08:00 ET
|
IO Biotech
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Jefferies London Healthcare Conference
October 31, 2022 08:00 ET
|
IO Biotech
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Appointment of New Chief Financial Officer
October 13, 2022 16:05 ET
|
IO Biotech
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...